<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844164</url>
  </required_header>
  <id_info>
    <org_study_id>ERC_2021/01</org_study_id>
    <secondary_id>19-15-00243</secondary_id>
    <nct_id>NCT04844164</nct_id>
  </id_info>
  <brief_title>Vitamin D Metabolism in Patients With Endocrine Disorders</brief_title>
  <official_title>Prospective Non-randomised Controlled Study of Vitamin D Metabolism in Patients With Endocrine Disorders (Acromegaly, Cushing's Disease, Primary Hyperparathyroidism, Diabetes Mellitus Type 1) Treated With Cholecalciferol Bolus Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endocrinology Research Centre, Moscow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Russian Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Endocrinology Research Centre, Moscow</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective controlled interventional study aims to reveal the diversity of vitamin D&#xD;
      metabolism in patients with certain endocrine disorders (Cushing's disease, acromegaly,&#xD;
      primary hyperparathyroidism, diabetes mellitus type 1) compared to healthy adults. All&#xD;
      patients will receive a single dose (150,000 IU) of cholecalciferol aqueous solution orally.&#xD;
      Laboratory assessments including serum vitamin D metabolites (25(OH)D3, 25(OH)D2,&#xD;
      1,25(OH)2D3, 3-epi-25(OH)D3, 24,25(OH)2D3 and D3), free 25(OH)D, vitamin D-binding protein&#xD;
      (DBP) and parathyroid hormone (PTH) as well as serum and urine biochemical parameters will be&#xD;
      performed before the intake and on Days 1, 3 and 7 after the administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline 25(OH)D3 level</measure>
    <time_frame>Day 0</time_frame>
    <description>Measured in ng\mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 25(OH)D3 level</measure>
    <time_frame>Day 1, 3, 7</time_frame>
    <description>Measured in ng\mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum total calcium</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in mmol\L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin-adjusted calcium</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in mmol\L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum phosphorus</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in mmol\L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PTH</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in Î¼mol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum magnesium</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in mmol\L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium-creatinine ratio in spot urine</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in mmol/mmol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorus-creatinine ratio in spot urine</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in mmol/mmol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,25(OH)2D3 level</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in pg\mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24,25(OH)2D3 level</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in ng\mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-epi-25(OH)D3 level</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in ng\mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D2 level</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in ng\mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D3 level</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in ng\mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D3/24,25(OH)2D3 ratio</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D3/1,25(OH)2D3 ratio</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free 25(OH)D</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum vitamin D-binding protein</measure>
    <time_frame>Day 0, 1, 3, 7</time_frame>
    <description>Measured in mg/L</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Pituitary ACTH Hypersecretion</condition>
  <condition>Acromegaly</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Primary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Cushing's Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Acromegaly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes Mellitus Type 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary Hyperparathyroidism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol 15000 UNT/ML Oral Solution</intervention_name>
    <description>A single dose (150,000 IU) of cholecalciferol aqueous solution per os</description>
    <arm_group_label>Acromegaly</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Cushing's Disease</arm_group_label>
    <arm_group_label>Diabetes Mellitus Type 1</arm_group_label>
    <arm_group_label>Primary Hyperparathyroidism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed diagnosis (arms &quot;Cushing's Disease&quot;, &quot;Acromegaly&quot;, &quot;Diabetes Mellitus Type&#xD;
             1&quot;, &quot;Primary Hyperparathyroidism&quot;)&#xD;
&#xD;
          -  active phase of the disease (arms &quot;Cushing's Disease&quot;, &quot;Acromegaly&quot;)&#xD;
&#xD;
          -  no history of surgical and specific pharmacological treatment (arm &quot;Primary&#xD;
             Hyperparathyroidism&quot;)&#xD;
&#xD;
          -  HbA1c &lt;8.0% (arm &quot;Diabetes Mellitus Type 1&quot;)&#xD;
&#xD;
          -  absence of the specified endocrine disorders (arm &quot;Control group&quot;)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  factors associated with vitamin D level&#xD;
&#xD;
               -  intake of the following drugs during the 3 months preceding the study: vitamin D&#xD;
                  medications; glucocorticosteroids; antiretroviral drugs; antifungal drugs;&#xD;
                  cholestyramine, orlistat; antiepileptic drugs; antidepressants (fluoxetine);&#xD;
                  diuretics (spironolactone); antimicrobial agents (macrolides, tetracyclines,&#xD;
                  isoniazid, rifampin, primaquine); chemotherapy (cyclophosphamide, tamoxifen,&#xD;
                  paclitaxel, ifosfamide, irinotecan, etoposide, vinblastine); immunosuppressants&#xD;
                  (cyclosporin A, tacrolimus, sirolimus); H2 receptor antagonists.&#xD;
&#xD;
               -  BMI &gt;35 kg/m2&#xD;
&#xD;
               -  pregnancy&#xD;
&#xD;
               -  granulomatous disease (sarcoidosis, tuberculosis, histoplasmosis, berylliosis,&#xD;
                  coccidiomycosis)&#xD;
&#xD;
               -  disease with malabsorption syndrome (Crohn's disease, ulcerative colitis, celiac&#xD;
                  disease, post-bariatric surgery condition, decompensation of chronic&#xD;
                  pancreatitis)&#xD;
&#xD;
               -  reduced renal function (eGFR &lt;60 ml/min/1.73m2)&#xD;
&#xD;
               -  laboratory signs of liver failure (hypoalbuminemia, hypoprothrombinemia)&#xD;
&#xD;
          -  hypercalcemia or risk factors for hypercalcemia&#xD;
&#xD;
               -  serum total calcium &gt;3.0 mmol/L&#xD;
&#xD;
               -  myeloma&#xD;
&#xD;
               -  immobilization&#xD;
&#xD;
               -  thiazide diuretics intake&#xD;
&#xD;
          -  allergy to vitamin D drugs&#xD;
&#xD;
          -  total 25(ÐÐ)D &gt;60 ng/ml (determined by chemiluminescent immunoanalysis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liudmila Rozhinskaya, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology Research Centre, Moscow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Povaliaeva, MD</last_name>
    <phone>+74991243422</phone>
    <phone_ext>9297</phone_ext>
    <email>povalyaeva.alexandra@endocrincentr.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Artem Zhukov, MD</last_name>
    <phone>+74991243422</phone>
    <phone_ext>3339</phone_ext>
    <email>jukov.artem@endocrincentr.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endocrinology Research Centre, Moscow</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Povaliaeva, MD</last_name>
      <phone>+74991243422</phone>
      <phone_ext>9297</phone_ext>
      <email>povalyaeva.alexandra@endocrincentr.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Povaliaeva A, Pigarova E, Zhukov A, Bogdanov V, Dzeranova L, Mel'nikova O, Pekareva E, Malysheva N, Ioutsi V, Nikankina L, Rozhinskaya L. Evaluation of Vitamin D Metabolism in Patients with Type 1 Diabetes Mellitus in the Setting of Cholecalciferol Treatment. Nutrients. 2020 Dec 18;12(12). pii: E3873. doi: 10.3390/nu12123873.</citation>
    <PMID>33352890</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>Chromatography, Liquid</keyword>
  <keyword>Tandem Mass Spectrometry</keyword>
  <keyword>Cholecalciferol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

